ID: h-SDA-2026-04-26-gap-debate-20260417-033
Hypothesis
Residual Vascular Amyloid Prevents Complete CSF p-tau217 Normalization, Requiring Composite Cessation Criteria
Cerebral amyloid angiopathy (CAA) maintains a reservoir of vascular amyloid that continues to drive tau pathology even after parenchymal amyloid clearance.
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Cerebral amyloid angiopathy (CAA) maintains a reservoir of vascular amyloid that continues to drive tau pathology even after parenchymal amyloid clearance. CSF p-tau217 may not fully normalize in patients with CAA, meaning p-tau217-based cessation thresholds require composite criteria incorporating CAA biomarkers (CAA-lobular microbleeds, vessel wall imaging) to prevent premature cessation. APOE ε4 carriers show delayed p-tau217 normalization due to enhanced vascular amyloid deposition that resists anti-Aβ antibody penetration.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["APOE<br/>Apolipoprotein E"]
B["CLU (Clusterin)<br/> chaperone"]
C["Vascular Amyloid<br/>Deposit"]
D["Residual Amyloid<br/>Clearance Blocked"]
E["Perivascular<br/>Inflammation"]
F["CSF Biomarker<br/>Normalization Impaired"]
G["Cognitive<br/>Recovery Blocked"]
A --> C
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
APOE ε4 carriers show delayed p-tau217 normalization due to enhanced CAA burden
Supports
Mixed amyloid pathologies complicate biomarker-based treatment cessation decisions
Supports
MRI SWI and vessel wall imaging can identify high-risk CAA features for patient stratification
Contradicts
APOE ε4 effects on p-tau217 may be independent of CAA rather than mediated by vascular amyloid
Contradicts
CAA burden does not consistently predict cognitive trajectory in anti-amyloid antibody trials
Contradicts
Degree of incomplete p-tau217 normalization attributable to CAA versus other factors unquantified
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — APOE
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for APOE, CLU from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for APOE, CLU.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0412
Events (7d)
1
Price History
▼3.3%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF APOE ε4 homozygous carriers versus APOE ε4-negative carriers receive anti-Aβ antibody monotherapy for 24 months, THEN ε4/ε4 carriers will show delayed and attenuated CSF p-tau217 normalization (tro | Time to CSF p-tau217 nadir: APOE ε4/ε4 carriers ≥ 24 months; APOE ε4-negative carriers ≤ 12 months; final normalized p-tau217 in ε4/ε4 carriers remains 20-40% a | — no observation — | pending | 0.58 |
| IF patients with baseline CAA biomarkers (≥2 lobular microbleeds on SWI-MRI or positive vessel wall imaging) versus patients without CAA biomarkers receive anti-Aβ antibody therapy (lecanemab or donan | Mean CSF p-tau217 percent change from baseline at month 18: CAA+ < 30% reduction; CAA− > 50% reduction; between-group difference > 20 percentage points (p < 0.0 | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF patients with baseline CAA biomarkers (≥2 lobular microbleeds on SWI-MRI or positive vessel wall imaging) versus patients without CAA biomarkers receive anti-Aβ antibody therapy (lecanemab or donanemab) for 18 months, THEN the CAA+ group will demonstrate significantly smaller mean CSF p-tau217 re
Predicted outcome: Mean CSF p-tau217 percent change from baseline at month 18: CAA+ < 30% reduction; CAA− > 50% reduction; between-group difference > 20 percentage point
Falsification: CAA+ and CAA− groups achieve equivalent mean CSF p-tau217 reductions (>50%) with no statistically significant difference, disproving the vascular amyloid reservoir effect on tau pathology normalizatio
pendingconf 58%
IF APOE ε4 homozygous carriers versus APOE ε4-negative carriers receive anti-Aβ antibody monotherapy for 24 months, THEN ε4/ε4 carriers will show delayed and attenuated CSF p-tau217 normalization (trough level reached at month 24) compared to ε4-negative carriers (trough level reached at month 12),
Predicted outcome: Time to CSF p-tau217 nadir: APOE ε4/ε4 carriers ≥ 24 months; APOE ε4-negative carriers ≤ 12 months; final normalized p-tau217 in ε4/ε4 carriers remain
Falsification: APOE ε4/ε4 carriers achieve equivalent or faster CSF p-tau217 normalization kinetics compared to ε4-negative carriers, with both groups fully normalizing to reference range by month 18, disproving the
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.